Evidence map›Paper›PMID 16940117›Full record

Trial reportAntimicrobial agents and chemotherapy2006

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

Edwin DeJesus, Peter J Piliero, Kim Summers, Mary Beth Wire, Daniel S Stein, Amanda Masterman, Yu Lou, Sherene S Min, Mark J Shelton

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Edwin DeJesusOrlando Immunology Center, Florida, USA.
Peter J Piliero
Kim Summers
Mary Beth Wire
Daniel S Stein
Amanda Masterman
Yu Lou
Sherene S Min
Mark J Shelton
Research Triangle Park Foundation · USBoehringer Ingelheim (United States) · USGlaxoSmithKline (Canada) · CAOrlando Immunology Center · USSanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fosamprenavir (FPV) with and without ritonavir (RTV) was added to the antiretroviral regimens of human immunodeficiency virus-infected subjects receiving nevirapine (NVP) to evaluate this drug interaction. Significant reductions in plasma amprenavir exposure (25 to 35%) were observed following coadministration of 1,400 mg of FPV twice a day (BID) and 200 mg of NVP BID. A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment.

Indexed as

HIVAdultAnti-HIV AgentsCarbamatesDrug InteractionsFemaleFuransHIV InfectionsHIV Protease InhibitorsHumansMaleNevirapineOrganophosphatesReverse Transcriptase InhibitorsRitonavirSulfonamidesAnti-HIV AgentsCarbamatesfosamprenavirFuransHIV Protease InhibitorsNevirapineOrganophosphatesReverse Transcriptase InhibitorsRitonavirSulfonamides

Identifiers

PMID16940117
PMCPMC1563559
OpenAlexW2114211214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.